AstraZeneca (NYSE:AZN) and collaboration partner Merck (NYSE:MRK) announce the successful outcome of a Phase 3 clinical trial, PAOLA-1, evaluating PARP inhibitor Lynparza (olaparib), added to standard of care bevacizumab [Roche’s (OTCQX:RHHBY) Avastin] compared to bevacizumab alone, in women with advanced ovarian cancer with or without BRCA mutations in a first-line maintenance setting.
The study met the primary endpoint of a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to bevacizumab alone.
Detailed results will be presented at an upcoming medical conference.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.